Clinical Study

Entry, Retention, and Virological Suppression in an HIV Cohort Study in India: Description of the Cascade of Care and Implications for Reducing HIV-Related Mortality in Low- and Middle-Income Countries

Gerardo Alvarez-Uria, Raghavakalyan Pakam, Manoranjan Midde, and Praveen Kumar Naik

Department of Infectious Diseases, Rural Development Trust Hospital, Kadiri Road, Bathalapalli, Anantapur District, Andhra Pradesh 515661, India

Correspondence should be addressed to Gerardo Alvarez-Uria; gerardouria@gmail.com

Received 15 March 2013; Accepted 16 June 2013

Academic Editor: Thomas Nyirenda

Copyright © 2013 Gerardo Alvarez-Uria et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HIV treatment, care, and support programmes in low- and middle-income countries have traditionally focused more on patients remaining in care after the initiation of antiretroviral therapy (ART) than on earlier stages of care. This study describes the cumulative retention from HIV diagnosis to the achievement of virological suppression after ART initiation in an HIV cohort study in India. Of all patients diagnosed with HIV, 70% entered into care within three months. 65% of patients ineligible for ART at the first assessment were retained in pre-ART care. 67% of those eligible for ART initiated treatment within three months. 30% of patients who initiated ART died or were lost to follow-up, and 82% achieved virological suppression in the last viral load determination. Most attrition occurred in the pre-ART stages of care, and it was estimated that only 31% of patients diagnosed with HIV engaged in care and achieved virological suppression after ART initiation. The total mortality attributable to pre-ART attrition was considerably higher than the mortality for not achieving virological suppression. This study indicates that early entry into pre-ART care along with timely initiation of ART is more likely to reduce HIV-related mortality compared to achieving virological suppression.

1. Introduction

By the end of 2011, more than 90% of the 34 million people infected with HIV worldwide were living in low- or middle-income countries [1]. 16.88 billion was invested globally into HIV in 2011 and, in low- and middle-income countries, 89% of the investment was allocated to treatment care and support of HIV infected people [1].

One of the most important aims of the medical care of HIV patients is to initiate antiretroviral therapy (ART) before the development of HIV-related complications and to allow immunological recovery by maintaining long-term virological suppression. Despite important advances in the rollout of ART worldwide, 1.7 million people died of HIV-related pathologies in 2011 [1]. This high mortality could be explained by many factors including late presentation of HIV [2–5], poor engagement in medical care [6–9], poor retention in pre-ART care [10–12], late or no initiation of ART [13–15], high levels of attrition from care after ART initiation [16, 17], and poor virological suppression in patients on ART [18].

When designing programmes aimed at providing treatment, care, and support to people living with HIV, it is important to understand the contributions of these factors to the overall HIV mortality, in order to improve the efficiency of HIV spending. To date, the majority of HIV research and funding have focused on the reduction of mortality and morbidity after ART initiation. However, research also suggests that inadequate engagement in pre-ART care may result in fewer people receiving ART and may increase the proportion of patients initiating ART late [19].

Most research about the retention in HIV programmes comes from the United States and Sub-Saharan Africa [17, 19–21]. Despite 2.4 million HIV infected people estimated to be living with HIV in India in 2009 [22], only 486,173 were
receiving ART under the national programme in January 2012 [23]. This study describes the engagement and retention in care of a large cohort of patients in Anantapur, India. In particular, we studied the proportion of patients who entered and were retained in care from the point of HIV diagnosis to HIV virological suppression. We aimed to estimate what stages were more important for reducing the mortality of people living with HIV.

2. Methods

2.1. Setting. The study was performed in Anantapur, a district situated in the south border of Andhra Pradesh, India, with a high prevalence of HIV infection in antenatal clinics [24]. The HIV epidemic in Anantapur is largely driven by heterosexual transmission and is characterized by poor socio-economic conditions and high levels of illiteracy in the HIV population [25]. Rural Development Trust (RDT) is a nongovernmental organization that provides medical care to HIV infected people free of cost, including medicines, consultations, hospital admission charges, CD4 cell count enumeration, and HIV viral load. The Vicente Ferrer HIV Cohort Study (VFHCS) is an open cohort study of all HIV infected patients who have attended RDT hospitals since June 2006. The characteristics of the cohort have been described in detail elsewhere [25]. For this study, we selected HIV infected adults (>15 years) living in Anantapur and diagnosed with HIV between January 1st 2007 and November 4th 2011. The selection of patients from the database was executed on September 14th 2012.

During this period, ART was available free of cost in the district, and the CD4 cell count threshold for initiating ART was 250 cells/μL in accordance with the 2006 World Health Organization (WHO) guidelines [26–28]. Patients who were lost to followup (LTFU) were actively searched by phone calls and home visits by outreach workers, and in those patients who had died, relatives were asked about the date of death of the patient.

2.2. Definitions. To assess the HIV care before ART initiation, we divided the pre-ART care into three stages according to recent recommendations based on the experience of studies performed in Sub-Saharan Africa [19, 29]. To describe the entry into pre-ART care, we calculated the time between the HIV diagnosis and the first determination of the CD4 count (Stage 1). For HIV infected patients who were not eligible for ART at the first assessment, the Indian National Guidelines recommend performing CD4 count determinations every six months [26]. To describe the retention in pre-ART care of these patients (Stage 2), we calculated the number of completed semesters that patients had a CD4 count determination during the period starting at three months after the first CD4 count determination and finishing at the first CD4 cell count determination <250 cells/μL, death, or November 4th 2011, whatever occurred first (follow-up period). To be considered retained in pre-ART care, patients should have had a CD4 count determination in all the semesters of followup. However, if a patient had a CD4 count >250 cells/μL in the last 12 months of followup, they were considered retained in pre-ART care regardless of the number of previous semesters without CD4 count determinations [29]. To be included in the Stage 2 analysis, patients should have had at least a follow-up period of six months (one complete semester after three months from the first CD4 count determination). For example, for a patient who had the first CD4 count determination on October 1st, 2009 and died on January 15th, 2011, we checked whether the patient had a CD4 count determination from January 1st, 2010 (three months after the first CD4 count determination) to June 30th, 2010 (first semester) and from July 1st, 2010 to December 31st, 2010 (second semester). If he had CD4 count determinations during the first and second semesters, the patient was considered retained in care. If he had a CD4 count determination only in one semester, he did not meet criteria for being considered retained in pre-ART care. However, if the same patient had a CD4 lymphocyte count >250 cells/μL in the last 12 months of followup, he was considered retained in care even if he did not have CD4 count determinations in all the semesters of followup. To describe the promptness of ART initiation, we calculated the time from the first CD4 count <250 cells/μL to the initiation of ART (Stage 3).

After ART initiation, patients were considered LTFU if they did not come to the clinics for at least 180 days after their last scheduled appointment. Patients on ART were considered retained in care if they did not stop ART for any reason, were not LTFU, and did not die (Stage 4). Virological suppression was defined as having an HIV viral load <400 copies/mL after six months of ART initiation in the last viral load determination (Stage 5). After completion of each stage, patients who transferred to other clinics were not included in the analysis of the next stage [29].

2.3. Statistical Analysis. Statistical analysis was performed using Stata Statistical software (Stata Corporation, Release 11, College Station, TX, USA). Confidence intervals for proportions were calculated using the Wilson method [30]. We used Kaplan-Meier survival estimates for calculating cumulative incidences of mortality for each stage of care. This study was approved by the Ethical Committee of the RDT Hospital.

3. Results

The number of patients included in each stage is summarized in Figure 1. We identified 7814 patients diagnosed with HIV infection and 7701 were included in the Stage 1 analysis. 6287 (81.6%) patients had a CD4 count determination. Of 2790 patients who were not eligible for ART at the first assessment, 1696 patients met the inclusion criteria for the Stage 2 analysis. During the study period, we identified 4152 patients who were eligible for ART initiation, and 4105 of them were included in the Stage 3 analysis. ART was initiated in 3208 (78.1%) patients and 3169 were included in the Stage 4 analysis. Of these 3169 patients, 1946 (61.4%) had a viral load determination after six months of ART and they were
HIV infection diagnosis (n = 7814)

Stage 1 analysis (n = 7701)

CD4 cell count available (n = 6287)

CD4 not available (n = 1414)

Not eligible for ART at first CD4 count (n = 2790)

Criteria for Stage 2 analysis met (n = 1752)

Stage 2 analysis (n = 1696)

113 transferred

56 transferred

Eligible for ART during followup (n = 701)

Eligible for ART* (n = 4152)

Stage 3 analysis (n = 4105)

ART initiated (n = 3208)

ART not initiated (n = 897)

Stage 4 analysis (n = 3169)

Viral load available (n = 1946)

Viral load not available (n = 1223)

Included in the Stage 5 analysis. Kaplan-Meier survival curves at different stages of HIV care are presented in Figure 2.

3.1 Stage 1. Of 7701 patients diagnosed with HIV infection, 70.3% (n = 5410) entered into care within three months of HIV diagnosis. The median CD4 count of patients who entered into care was 216 cells/μL (interquartile range [IQR], 106–398). Kaplan-Meier survival curves at Stage 1 are presented in Figure 2(a). Patients who entered into care within three months of HIV diagnosis had lower mortality than patients who did not (P = 0.0001). The estimated five-year mortality difference between the two groups was 7.5% (95% CI, 4.2–10.9).

3.2 Stage 2. Of 1696 patients included in the Stage 2 analysis, 26.3% (n = 446) had CD4 count determinations in all semesters of followup. Of 1250 patients who did not have CD4 count determinations in all semesters, 662 (53%) had a CD4 count >250 cells/μL in the last 12 months of followup. Hence, 65.3% (n = 1108) were considered as retained in pre-ART care according to study criteria. The median pre-ART
follow-up was three semesters (IQR, 1–5). Kaplan-Meier survival curves at Stage 2 are presented in Figure 2(b). Patients who were retained in pre-ART care had lower mortality than patients who were not retained in pre-ART care \((P = 0.0043)\). The estimated five-year mortality difference between the two groups was 11.7% (95% CI, 2.7–20.6). However, when comparing mortality by CD4 count at entry into care (Figures 2(c) and 2(d)), we did not observe significant differences in patients having CD4 count >350 cells/\(\mu\)L \((P = 0.1053)\).

### Stage 3

Of 4105 patients eligible for ART, 67.3% \((n = 2761)\) initiated ART within three months of becoming eligible. Kaplan-Meier survival curves at Stage 3 are presented in Figure 2(e). Patients who initiated ART within three months had lower mortality than patients who did not \((P < 0.0001)\). The estimated five-year mortality difference between the two groups was 28.7% (95% CI, 23–34.4). Differences in mortality were more pronounced for patients with CD4 count <200 cells/\(\mu\)L (Figures 2(f), 2(g), and 2(h)). Looking at the Kaplan-Meier survival curves for Stage 3, we can observe that an important proportion of patients who did not initiate ART within three months died during the initial period of follow-up. Considering that many of these patients might be too sick to initiate ART and that the positive effect of ART on survival is observed only after a few weeks of treatment [31], we also calculated the five-year mortality differences.
between patients who did and did not initiate ART within three months including only those patients having >3 months of followup (i.e., did not die or were not LTFU within three months of becoming eligible for ART), which was 19.9% (95% CI, 13–26.7).

3.4. Stages 4 and 5. Of 3169 patients who initiated ART, 15% (n = 480) died, 15% (n = 474) were LTFU, and 0.7% (n = 23) stopped ART. Of 1946 patients who had a viral load determination after six months of ART initiation, 81.8% (n = 1591) achieved virological suppression (<400 copies/mL) in the last viral load determination. The median time from the ART initiation to the last viral load determination was 2.26 years (IQR, 1.33–3.31). Kaplan-Meier survival curves at Stage 5 are presented in Figure 2(i). Patients who achieved virological suppression had lower mortality than patients who did not achieve virological suppression (P = 0.0004). The estimated five-year mortality difference between the two groups was 8.7% (95% CI, 2.3–15).

3.5. Combinations of All Stages. Outcomes for each stage of HIV care are summarized in detail in Table 1. Of 7701 patients diagnosed with HIV, 1414 (18.4%) did not enter into care. Of 1696 patients who were ART ineligible at the first assessment and met inclusion criteria for the Stage 2 analysis, 531 (31.3%) were not retained in pre-ART care and did not come back to the clinics, so we estimated that 31.3% of the 44.4% of patients who were not eligible for ART at the first assessment (i.e., 13.9% of all patients who entered into care) were not retained in pre-ART care. Of 4105 patients who were eligible for ART, 897 (21.9%) did not initiate ART. Of 3169 patients who initiated ART, 977 (30.8%) were not retained in care. Of 1790 patients who were retained in care after ART initiation (i.e., did not die, were not LTFU, and did not stop ART) and had a viral load determination after six months of initiating ART, 309 (17.3%) did not achieve virological control (<400 copies/mL) in the last viral load determination. Taking into account the attrition at each stage, we calculated the cumulative retention in care during the period of the study (Figure 3). According to this estimation, only 31.4% of patients diagnosed with HIV in our setting followed all stages of care. In Figure 4, we made a simulation of the number of potential lives saved out of 1000 patients diagnosed with HIV with...
hypothesised HIV programmes that could achieve a 100% success in the different stages of HIV care. The calculations were performed taking into account: (i) the differences in the five-year mortality between patients who did and did not achieve the objectives for Stage 1 (entry into care within three months), Stage 2 (retention in pre-ART care prior to ART eligibility), Stage 3 (initiation of ART within three months of eligibility), and Stage 5 (virological suppression); (ii) the cumulative retention for Stage 1 (patients with HIV diagnosis, i.e., 100%), Stage 2 (patients who entered into care but were ineligible for ART at the first assessment, i.e., 36.2%), Stage 3 (patients retained in pre-ART care, i.e., 70.3%), and Stage 5 (patients retained in care >6 months after ART initiation, i.e., 45.4%); and Stage 5 (virological suppression). The proportion of patients who did not achieve the objectives for Stages 1, 2, 3, and 5 (Table 1). Some patients who died within three months of ART eligibility did not initiate ART because they were too sick and early initiation of ART would not have improved their prognosis. Thus, with the intention of being conservative in our calculations, we used the five-year mortality difference between patients who did and did not initiate ART within three months of ART eligibility who had >3 months of follow-up to estimate the potential impact of improving Stage 3 in HIV programmes. Nevertheless, the highest potential impact for reducing the mortality in HIV programmes was observed at Stage 3 (3.38%, 95% CI 2.21–4.54) followed by Stage 1 (2.23%, 95% CI 1.24–3.23), Stage 2 (1.47%, 95% CI 0.34–2.59), and Stage 5 (0.72%, 95% CI 0.19–1.24).

4. Discussion

In this cohort study, we found that less than one-third of people diagnosed with HIV followed all stages of care from diagnosis to the achievement of virological suppression after ART initiation, and that attrition was higher in pre-ART stages than after ART initiation. Although the study is limited to a small area of India and comparisons among studies are difficult because of different operational definitions [29], our results are in accordance with other studies performed in resource-limited settings. In two systematic reviews of the retention in care in Sub-Saharan Africa, less than one third of patients were retained in care prior to ART initiation, and only 65%, of those who initiated ART, were retained in care after three years of follow-up [17, 19]. In a meta-analysis of the pre-ART attrition in Sub-Saharan Africa [21], the attrition in Stage 1 was 22.4% and the attrition in Stage 3 was 37.1%. In a single site cohort study in South Africa [32], the cumulative retention in care of ART eligible patients from HIV diagnosis to 6–12 months after ART initiation was 36.9%. Although these studies differ in some of the stage definitions and follow-up periods, the rates of attrition are similar to our study, suggesting comparable rates of attrition in Sub-Saharan Africa and India.

Despite notable achievements, the mortality due to HIV in developing countries is still high [1]. Governments in low- and middle-income countries are making efforts to reduce this high mortality, but resources and monitoring are focused more on patients on ART than on pre-ART stages of care [33]. However, the results of this study show that improving pre-ART stages of care can have greater impact on reducing HIV mortality than achieving virological suppression. Moreover, previous studies have shown that interventions to improve engagement in care can be cost-effective [34–36]. These data indicate that stakeholders and donors should consider placing more emphasis on promoting research and implementing evidence-based interventions to improve entry and retention in pre-ART care [37, 38].

To our knowledge, this is one of the first studies to follow patients from the diagnosis of HIV to the achievement of virological suppression in a resource-limited setting. In the United States, it is estimated that 80% of HIV infected patients have been diagnosed with HIV; 77% of patients diagnosed with HIV enter into care within 3-4 months of diagnosis; 66.2% of patients linked to care are retained in care; and 77% of patients on ART achieve virological suppression [20]. In our cohort, 70.3% of patients diagnosed with HIV entered into care within three months; 46.5% of patients linked to care were retained in care; and 81.8% of patients on ART achieved virological suppression. The total number of people diagnosed with HIV in the district is not known, but in 2011 it is estimated that the number of people living with HIV was 26,800, and by November 2011, 14,395 patients were registered in Government ART Centres [22, 39–41]. Therefore, only 54% of the estimated HIV infected people in the district entered into care, which compares unfavourably with the 61.6% HIV infected patients who enter into care in the United States [20]. A similar observation is made with the difference in CD4 counts at entry into care in our cohort (216 cells/μL, IQR 106–398) compared with the United States and Canada (317 cells/μL, IQR 135–517) [2]. These data suggest that, compared to North America, in our setting a lower proportion of patients enter into care, initial CD4 counts are lower, there is more attrition (mortality and loss to follow up) after engagement in care, and similar proportions of patients achieve virological suppression.

In our study, there was no significant increase in mortality among patients who had an initial CD4 count >350 cells/μL and poor retention in pre-ART care. In the 2010 WHO guidelines [33], the CD4 count threshold for initiating ART has been raised to 350 cells/μL. Thus, the proportion of patients who will become eligible for ART soon after the HIV diagnosis will increase considerably [5]. Previous studies have shown a reduction in mortality and loss to follow up when ART is initiated with CD4 >200 cells/μL [42–44]. Therefore, it is likely that the implementation of the 2010 WHO guidelines will reduce both the mortality due to poor retention in pre-ART care and attrition after ART initiation.

To define the stages of pre-ART care, we used the date of collection of the CD4 count sample, rather than the date patients are informed of their CD4 count result. Although the CD4 count notification date has been recommended by some authors [29], most patients are informed of their results at the next clinical visit, which for patients in pre-ART care may occur many months later [11, 32]. Using the CD4 count sample date to monitor the performance of HIV programmes in pre-ART stages can encourage these programmes to implement effective strategies (e.g., phone...
calls, home visits, etc.) aimed at informing ART eligible patients of the need for prompt initiation of therapy.

The study has some limitations. The proportion of patients diagnosed with HIV who never entered into care is likely to be underestimated. HIV testing is performed in different locations, and patients diagnosed in other healthcare facilities and never entered into care were not identified. We estimated the proportion of ART-ineligible patients who were not retained in pre-ART care, but not all of them were followed up until becoming eligible for ART. Therefore, it is possible that longer follow-up periods may result in higher rates of Stage 2 attrition. Moreover, patients LTFU at any stage may not be lost forever, as they may reengage in the future or enroll in other ART centres. However, patients LTFU are more likely to initiate ART with low CD4 counts or may die before attending other healthcare facilities [45].

5. Conclusions

This study shows that less than one third of patients diagnosed with HIV in our setting follow all the stages of care up to the achievement of virological suppression after ART initiation. Most attrition occurs in pre-ART stages, and the mortality attributable to pre-ART attrition is considerably higher than the mortality due to lack of virological suppression after ART initiation. Considering that other studies in low- and middle-income countries had similar results, it should be recommended that HIV programmes monitor their performance in pre-ART stages of care. Implementing new strategies to improve the link between HIV testing and pre-ART care and timely initiation of ART would help reduce the mortality of people living with HIV in resource-limited settings.

Acknowledgment

The authors would like to thank Leann Johnson for her critical review of the paper.

References

[1] UNAIDS, “2012 UNAIDS Report on the Global AIDS Epidemic,” 2012, http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121220_UNAIDS_Global_Report_2012_en.pdf.

[2] K. N. Althoff, S. J. Gange, M. B. Klein et al., “Late presentation for human immunodeficiency virus care in the United States and Canada,” Clinical Infectious Diseases, vol. 50, no. 11, pp. 1512–1520, 2010.

[3] A. Adler, S. Mounier-Jack, and R. J. Coker, “Late diagnosis of HIV in Europe: definitional and public health challenges,” AIDS Care, vol. 21, no. 3, pp. 284–293, 2009.

[4] E. Girardi, C. A. Sabin, and A. D. Monforte, “Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, supplement 1, pp. S3–S8, 2007.

[5] G. Alvarez-Uria, M. Middel, R. Pakam, S. Kannan, L. Bachu, and P. K. Naik, “Factors associated with late presentation of HIV and estimation of antiretroviral treatment need according to CD4 lymphocyte count in a resource-limited setting: data from an HIV cohort study in India,” Interdisciplinary Perspectives on Infectious Diseases, vol. 2012, Article ID 293795, 7 pages, 2012.

[6] I. V. Bassett, S. Regan, S. Chetty et al., “Who starts antiretroviral therapy in Durban, South Africa? Not everyone who should,” AIDS, vol. 24, supplement 1, pp. S37–S44, 2010.

[7] K. Kranzer, J. Zeinecker, P. Ginsberg et al., “Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa,” PLoS ONE, vol. 5, no. 11, Article ID e13801, 2010.

[8] B. A. Larson, A. Brennan, L. McNamara et al., “Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa,” Bulletin of the World Health Organization, vol. 88, no. 9, pp. 675–680, 2010.

[9] E. Losina, I. V. Bassett, J. Giddy et al., “The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa,” PLoS ONE, vol. 5, no. 3, Article ID e9538, 2010.

[10] B. A. Larson, A. Brennan, L. McNamara et al., “Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa,” Tropical Medicine and International Health, vol. 15, no. 1, pp. 43–47, 2010.

[11] R. J. Lessells, P. C. Mutevedzi, G. S. Cooke, and M. L. Newell, “Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural kwazulu-natal, South Africa,” Journal of Acquired Immune Deficiency Syndromes, vol. 56, no. 3, pp. e79–e86, 2011.

[12] K. Tayler-Smith, R. Zachariah, M. Massquoi et al., “Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system?” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 104, no. 5, pp. 313–319, 2010.

[13] I. V. Bassett, B. Wang, S. Chetty et al., “Loss to care and death before antiretroviral therapy in Durban, South Africa,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 2, pp. 135–139, 2009.

[14] B. Amuron, G. Namara, J. Birungi et al., “Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda,” BMC Public Health, vol. 9, article 290, 2009.

[15] S. M. Ingle, M. May, K. Uebel et al., “Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study,” AIDS, vol. 24, no. 17, pp. 2717–2725, 2010.

[16] M. A. Micek, K. Gimbel-Sherr, A. J. Baptista et al., “Loss to follow-up of adults in public HIV care systems in central mozambique: identifying obstacles to treatment,” Journal of Acquired Immune Deficiency Syndromes, vol. 52, no. 3, pp. 397–405, 2009.

[17] M. P. Fox and S. Rosen, “Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007—2009: systematic review,” Tropical Medicine and International Health, vol. 15, no. 1, pp. 1–15, 2010.

[18] R. E. Barth, M. F. S. van der Loeff, R. Schuurman, A. I. Hoepelman, and A. M. J. Wensing, “Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review,” The Lancet Infectious Diseases, vol. 10, no. 3, pp. 155–166, 2010.

[19] S. Rosen and M. P. Fox, “Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review,” PLoS Medicine, vol. 8, no. 7, Article ID e1001056, 2011.
20. "Vital signs: HIV prevention through care and treatment—United States," Morbidity and Mortality Weekly Report, vol. 60, pp. 1618–1623, 2011.
21. C. Mugglin, J. Estill, G. Wandeler et al., “Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis,” Tropical Medicine and International Health, vol. 17, no. 12, pp. 1509–1520, 2012.
22. National AIDS Control Organisation, “India HIV Estimates,” Tech. Rep., 2011, http://naco.gov.in/upload/Surveillance/Reports%20%20Publications/HSS%202010-11%20Technical%20Brief_30%20Nov%202012.pdf.
23. National AIDS Control Organisation, “Total number of patients alive and on ART,” 2012, http://www.nacoonline.org/upload/HIV%20data/Patients%20alive%20and%20on%20ART%20Jan%202012.pdf.
24. National AIDS Control Organisation, “HIV Sentinel Surveillance 2010-11,” A Technical Brief, 2012, http://naco.gov.in/upload/Surveillance/Reports%20%20Publication/HSS%202010-11%20Technical%20Brief_30%20Nov%202012.pdf.
25. G. Alvarez-Uria, M. Midde, R. Pakam, and P. K. Naik, “Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India,” Infectious Disease Reports, vol. 4, no. 1, article e19, 2012.
26. National AIDS Control Organisation and Ministry of Health & Family Welfare Government of India, Antiretroviral Therapy Guidelines for HIV Infected Adults and Adolescents Including Post-Exposure, 2007, http://nacoonline.org/upload/Policies%20%20Guidelines%20Antiretroviral%20Therapy%20Guidelines%20for%20HIV%20Infected%20Adults%20and%20Adolescents%20Including%20Post-exposure.pdf.
27. Panos, “Antiretroviral drugs for all? Obstacles in accessing treatment Lessons from India,” 2007, http://www.panossouthasia.org/pdf/Antiretrovirals.pdf.
28. WHO, “Antiretroviral therapy for HIV infection in adults and adolescents,” 2006, http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.
29. M. P. Fox, B. Larson, and S. Rosen, “Defining retention and attrition in pre-antiretroviral HIV care: proposals based on experience in Africa,” Tropical Medicine and International Health, vol. 17, no. 10, pp. 1235–1244, 2012.
30. A. Agresti and B. A. Coull, “Approximate is better than “exact” for interval estimation of binomial proportions,” The American Statistician, vol. 52, no. 2, pp. 119–126, 1998.
31. A. R. Zolopa, J. Andersen, L. Komarow et al., “Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial,” PLoS ONE, vol. 4, no. 5, Article ID e5575, 2009.
32. K. Clouse, A. E. Pettifor, M. Maskew et al., “Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa,” Journal of Acquired Immune Deficiency Syndromes, vol. 62, no. 2, pp. e39–e46, 2013.
33. World Health Organization, “Antiretroviral therapy for HIV infection in adults and adolescents,” 2010, http://www.who.int/hiv/pub/arp/adult2010/en/index.html.
34. L. Muhamadi, N. M. Tumwesigye, D. Kadobera et al., “A Single-Blind randomized controlled trial to evaluate the effect of extended counseling on uptake of pre-antiretroviral care in Eastern Uganda,” Trials, vol. 12, article 184, 2011.
35. E. Losina, H. Tourné, L. M. Uhler et al., “Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d’Ivoire appraisal,” PLoS Medicine, vol. 6, no. 10, Article ID e1000173, 2009.
36. G. P. Bisson and J. S. A. Stringer, “Lost but not forgotten—the economics of improving patient retention in AIDS treatment orograms,” PLoS Medicine, vol. 6, no. 10, Article ID e1000174, 2009.
37. M. A. Thompson, M. J. Mugavero, K. R. Amico et al., “Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an international association of physicians in AIDS care panel,” Annals of Internal Medicine, vol. 156, no. 11, pp. 817–833, 2012.
38. M. L. Scanlon and R. C. Vreeman, “Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings,” HIV AIDS, vol. 5, pp. 1–17, 2013.
39. Office of The Registrar General & Census Commissioner, Census of India, New Delhi, India, 2011.
40. Andhra Pradesh AIDS Control Society (n.d.), “2010-2011 ART Report,” 2012, http://www.apsacs.org/index1.html.
41. Andhra Pradesh AIDS Control Society, “ANC HIV Sentinel Surveillance 2010 Bulletin,” 2010, http://www.apsacs.org/HSS%20BULLETIN.pdf.
42. N. Ford, K. Kranzer, K. Hilderbrand et al., “Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho,” AIDS, vol. 24, no. 17, pp. 2645–2650, 2010.
43. K. Clouse, A. Pettifor, M. Maskew et al., “Initiating ART when presenting with higher CD4 counts results in reduced loss to follow-up in South Africa,” AIDS, vol. 27, no. 4, pp. 645–650, 2013.
44. M. P. Fox, I. M. Sanne, F. Conradie et al., “Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South Africa,” AIDS, vol. 24, no. 13, pp. 2041–2050, 2010.
45. M. W. G. Brinkhof, M. Pujades-Rodriguez, and M. Egger, “Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis,” PLoS ONE, vol. 4, no. 6, Article ID e5790, 2009.